Clinical and molecular characterization of Costello syndrome in unrelated Mexican patients

This study intends to describe for the first time a cohort of Mexican patients with Costello syndrome. The five exons of the HRAS gene were amplified in DNA samples from 13 patients with a clinical suspicion of Costello syndrome. PCR products were sequenced using the Ready Reaction Big Dye Terminator v.3.0 Kit and an ABI PRISM 310 sequencer. Only five patients (38%) showed causal variant in codon 12 of the HRAS gene (four with the p.Gly12Ser and one with the p.Gly12Ala variant). Three patients showed silent polymorphic variants (p.His27His and p.Leu159Leu). Clinical features in patients carrying the causal variant were variable. The alternative diagnosis of cardio-facio-cutaneous syndrome was considered in patients who did not have a causative variant in HRAS.

[1]  K. Gripp,et al.  Attenuated phenotype of Costello syndrome and early death in a patient with an HRAS mutation (c.179G>T; p.Gly60Val) affecting signalling dynamics , 2017, Clinical genetics.

[2]  K. Gripp,et al.  Phenotypic spectrum of Costello syndrome individuals harboring the rare HRAS mutation p.Gly13Asp , 2017, American journal of medical genetics. Part A.

[3]  A. Jezela-Stanek,et al.  Novel pathogenic variant in the HRAS gene with lethal outcome and a broad phenotypic spectrum among Polish patients with Costello syndrome , 2017, Clinical dysmorphology.

[4]  K. Gripp,et al.  An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences , 2015, American journal of medical genetics. Part A.

[5]  G. McVean,et al.  Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline , 2013, Proceedings of the National Academy of Sciences.

[6]  G. Rosenberger,et al.  Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome. , 2013, Human molecular genetics.

[7]  K. Rauen,et al.  Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development , 2012, The British journal of dermatology.

[8]  K. Gripp,et al.  Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations , 2011, Genetics in Medicine.

[9]  R. Tenconi,et al.  Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C , 2011, American journal of medical genetics. Part A.

[10]  K. Gripp,et al.  Costello syndrome associated with novel germline HRAS mutations: An attenuated phenotype? , 2008, American journal of medical genetics. Part A.

[11]  K. Rauen.  HRAS and the Costello syndrome , 2007, Clinical genetics.

[12]  W. Reardon,et al.  Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases , 2005, Journal of Medical Genetics.

[13]  Yukichi Tanaka,et al.  Germline mutations in HRAS proto-oncogene cause Costello syndrome , 2005, Nature Genetics.

[14]  S. Parraguirre-Martínez,et al.  [Costello syndrome associated to a neuroblastoma. Presentation of a case]. , 2000, Gaceta medica de Mexico.

[15]  Piero Carninci,et al.  A fast method for high-quality genomic DNA extraction from whole human blood. , 1991, BioTechniques.

[16]  F. Beemer,et al.  New syndrome. , 1982, American journal of medical genetics.

[17]  J. Costello.  A New Syndrome: Mental Subnormality and Nasal Papillomata , 1977, Australian paediatric journal.